Table 2 Proportion of variation of CSF t-tau biomarker levels explained by biomarkers of synaptic degeneration and neurodegeneration
Model | pR2 | pR2 (%) | R2 | ΔpR2 | AIC |
|---|---|---|---|---|---|
Cognitively unimpaired | |||||
Full | - | - | 0.90 | - | 154a,b |
Neurodegeneration | 0.12 ± 0.05 | 15.0% | 0.26 | 0.52 | 518b |
Synapse degeneration | 0.86 ± 0.02 | 95.3% | 0.78 | −0.52 | 179 |
Cognitively impaired | |||||
Full | - | - | 0.82 | - | 146a,b |
Neurodegeneration | 0.17 ± 0.07 | 23.6% | 0.29 | 0.48 | 258b |
Synapse degeneration | 0.74 ± 0.04 | 90.3% | 0.77 | −0.48 | 163 |